NCI Launches Two New Efforts to Recruit Patients Into Clinical Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 6
Volume 7
Issue 6

BETHESDA, Md--The National Cancer Institute has published a new brochure and opened a new website, both designed to encourage cancer patients to enroll in clinical trials. "Taking Part in Clinical Trials: What Cancer Patients Need to Know" provides an overview of cancer treatment trials and answers questions that patients might have about them. Novartis Pharmaceuticals provided partial funding for the pamphlet.

BETHESDA, Md--The National Cancer Institute has published a new brochure and opened a new website, both designed to encourage cancer patients to enroll in clinical trials. "Taking Part in Clinical Trials: What Cancer Patients Need to Know" provides an overview of cancer treatment trials and answers questions that patients might have about them. Novartis Pharmaceuticals provided partial funding for the pamphlet.

NCI says its newest website is intended to meet the need "for accessible, far-reaching, and up-to-date information on cancer prevention, diagnosis, and treatment research." Information on the brochure and about joining a treatment trial is available by calling 1-800-4-CANCER or by visiting the website at http://cancertrials.nci.nih.gov.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content